A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Jun 2024 Status changed from active, no longer recruiting to completed.
- 15 Mar 2023 Planned End Date changed from 27 Feb 2023 to 27 Feb 2025.
- 15 Mar 2023 Planned primary completion date changed from 27 Feb 2023 to 27 Feb 2024.